Formulary IQ 2.0

First national payer to publish a Dawnzera policy. Tryngolza sHTG criteria simplified to a single TG threshold in Q2.

Medicaid plan with published Tryngolza coverage guideline requiring genetic or score-based FCS confirmation.

State-specific Dawnzera PA criteria document published.

Policy posture still forming for Dawnzera — medical-necessity review only, no published PA criteria set.

Regional Blue with early Dawnzera policy publication and a defined exception pathway.

Marketplace plan requiring specialist involvement and genetic confirmation for Tryngolza.

Medicaid-heavy. State-by-state variability on FCS diagnosis documentation requirements.

Accredo-exclusive dispensing for both Ionis products. Prior-prophylaxis step documented for HAE.

Diet-documentation requirement remains for Tryngolza FCS; sHTG policy not yet published.

Medicare-weighted book. Tryngolza FCS covered with specialist-only prescribing; Dawnzera policy pending.

Closed formulary with internal P&T review. No published Dawnzera policy — whitespace for launch.

Published Dawnzera PA criteria with a 12-month approval duration.

PBM-level template drives downstream Blue plans; template update expected next quarter.

Dawnzera added non-preferred with step through Takhzyro. FCS genetic confirmation required for Tryngolza.

Published Tryngolza pharmacy policy with 6-month initial authorization.